take backseat aducanumab reviv rais
fve includ chanc approv
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
think specialty-market-focus drug portfolio
extend oncolog
strategi root merger ms
drug avonex idec cancer drug rituxan rituxan market
penetr high patent unit state
deriv profit share roch expir howev
think subcutan rituxan well novel antibodi gazyva
allow
revenu avonex
longer-act plegridi gener billion annual sale
remain lead ms interferon drug acquir full right
ms antibodi tysabri billion annual sale
partner howev price power demand
inject ms portfolio slightli erod gener
version teva copaxon launch novel high-efficaci
drug reach market
oral ms drug tecfidera strong launch continu show
solid safeti efficaci data howev continu scrutini
formul patent revok europ
ipr decis valid led us assum
gener entri think vumer abil
improv gi toler head-to-head data tecfidera
posit partli off-set headwind assum
total oral ms drug sale declin howev
see signific royalti roch ocrevu approv
 europ help off-set pressur
ms franchis
outsid ms strong human genet valid
neurolog pipelin creat potenti off-set ms pressur spinal
muscular atrophi drug spinraza partner ioni reach
billion sale although novarti gene therapi
zolgensma approv may signific
uncertainti surround potenti approv aducanumab
alzheim think market underestim
remain pipelin includ continu partnership
ioni drug candid treat condit includ stroke
parkinson pain al
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
idec merg combin forc market
multipl sclerosi drug avonex idec cancer drug rituxan today
rituxan next-gener antibodi gazyva market via
collabor roch also market novel ms drug tysabri
tecfidera japan ms portfolio co-promot eisai
hemophilia therapi eloct alprolix partner sobi spun
part bioverativ sever drug candid
phase trial neurolog neurodegen diseas
launch spinraza partner ioni
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
take backseat aducanumab reviv
rais fve includ chanc approv oct
shock turn event third-quart
file food drug administr earli
base complet analysi two phase
studi engag emerg remov drug
valuat model march lower fair
valu estim per share firm
discontinu studi base futil analysi
howev new data discuss today earn
call persuad us add drug back model
instead prior probabl approv
uncertainti
surround weaker data engag studi result
rais fair valu estim per
share share remain under-valued despit
signific share appreci tuesday addit data
releas clinic trial alzheim diseas
meet decemb abl address concern
could return prior probabl approv
continu award wide moat base
stabil ms franchis diversif neurolog
spinraza solid neurolog pipelin although
highlight high uncertainti come
innov high-risk pipelin financi result quarter
support thesi growth ms revenu
spinraza growth driven ex-u uptak continu
assum tecfidera could see gener competit
base case hear novemb like
follow rule earli remain bullish
pipelin beyond aducanumab data readout begin
come frequent includ phase
parkinson data data recent acquir
dive deeper aducanumab stori develop
stop march futil analysi pool data
trial indic less
probabl meet primari endpoint howev
time alreadi indic emerg
studi trend posit engag
fulli realiz extent impact
protocol amend result trial analysi
releas today show data patient
aducanumab abl meet primari secondari
patient emerg studi engag studywhich
enrol earlier emerg impact
treatment protocol use prior amend
push patient toward lower dosesdid meet
endpoint analysi engag studi subset
patient receiv high uninterrupt dose drug
patient sometim suspend treatment due side
effect seem impli similar efficaci emerg
although caution statist around
analysi
data appear encourag assign
probabl approv given mani outstand question
make sens futil analysiswhich
smaller dataset skew toward first complet
mani receiv lower dose drug prior protocol
amendmentsdid tell full stori addit fda
board decis file approv
howev approv far certain still miss
key data could help explain continu
mysteri engag fail meet primari endpoint
high-dos patient emerg saw reduct
declin cognit function measur cdr-
sb rel placebo highli statist
signific understand patient treat
protocol amend receiv uninterrupt high
dose aducanumab best although engag studi
start one month ahead emerg mean patient
advanc treatment protocol amend
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
patient could opt either compet gene therapi
novarti zolgensma small-molecul therapi roche/ptc
think combin global sale avonex plegridi
continu fall high-single-digit declin annual
new competit expect tysabri declin
billion billion end
forecast jcv-posit patient switch
hit nearli billion assum see
roughli global sale assum gener
tecfidera off-set total
fumar revenu launch vumer
howev base case assum total fumar sale
fall roughli billion billion
assum probabl approv opicinumab
sale billion year forecast
see oper margin
remain rel flat model cost spinraza
profit-shar partner ioni vumer royalti
payment counter ocrevu royalti
overal think top line remain flat
share-repurchas activ enabl firm
achiev averag earn per share growth
period
still rate systemat risk surround share
averag use cost equiti
assumpt align capit cost assumpt
return equiti investor like demand
rel
inelast portfolio ms
treatment tecfidera may see gener competit earli
encourag higher dose put place clear
differ enough explain data
month trial addit inform releas ctad
decemb shed light much
impact engag earlier enrol whether
signific differ number patient
receiv interrupt dose due known brain-
swell side effect amyloid plaqu reduct
two studi
rais fair valu estim per
share ad probabl
aducanumab approv valuat model
amount billion probability-adjust sale
aducanumab includ alzheim relat
sale tau pipelin although continu
includ probabl approv tau antibodi
supranuclear palsi
spinraza nusinersen think sale peak
billion assum sale begin declin rather
plateau new patient treat spinraza
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
alzheim drug aducanumab demonstr
high-risk natur pipelin target
base-cas scenario expect tecfidera/vumer
sale fall around billion also assum
tysabri sale peak billion think
new patient add patient test seroneg
jc viru antibodi price power may
abl counter impact discontinu
seroposit patient new altern regimen ocrevu
long run scenario think oper margin
remain
bull-cas scenario -- valu per
share -- tysabri sale stay flat explicit
forecast period also assum tecfidera
vumer becom domin player ms market
allow secur billion annual sale
assum tecfidera patent hold
physician see vumer gi benefit tecfidera
signific also assum probabl
aducanumab approv scenario bear-cas
scenario valu per share assum
heavi discontinu new competit threat weigh
tysabri sale global tysabri sale declin
million also forecast minim sale
tecfidera/vumer assum gener
tecfidera gi benefit vumer
includ sale aducanumab bear-cas scenario
achiev strong profit success
three market product field oncolog
neuroimmunolog introduct tecfidera secur
firm domin share ms market think
barrier entri high potenti biosimilar
product strong strategi
maintain leadership ms price power
strong patient need novel therapi high
pipelin particularli product factor
contribut firm wide moat return invest
capit think averag mid-teen
explicit forecast period easili exceed
estim cost capit
rituxan remain standard care sever form
hematolog cancer collabor revenu receiv
partner roch boost margin
avonex lead interferon therapi ms
long-term safeti record rel conveni
tysabri achiev blockbust sale base outstand
efficaci despit rare seriou side effect think
effort target drug patient least like
experi side effect allow firm see continu
sale despit novel product cleaner safeti profil
howev expect combin sale tecfidera
vumer declin tecfidera billion
billion annual base gener tecfidera
except tecfidera current
blockbust biolog biosimilar competit
loom threat think signific manufactur
develop cost biosimilar maker expect
incur would slow eros sale product
limit number contend abil
compet price data qualiti may also issu
biosimilar first applic avonex biosimilar
reject base insuffici efficaci delay
discontinu rituxan biosimilar push
european launch tysabri like
lower-prior target biosimilar entrant given risk
monitor potenti seriou side effect certain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
see moat trend stabl think
introduct new product firm grow
late-stag pipelin off-set new competit
competit price pressur ms oncolog
increas think strong efficaci oral ms therapi
biogen tecfidera novarti gilenya inject
therapi roch launch ocrevu make
less like new patient start older inject
avonex tysabri addit payer
leverag price negoti assum
abl take avonex price increas
roughli annual net basi past sever
year think futur price chang
like closer mid-single-digit increas biogen
recent launch conveni interferon therapi
plegridi littl chang trend opinion
model high-single-digit declin combin
avonex/plegridi tysabri go forward addit
report revenu cancer therapi rituxan
matur biosimilar competit
howev think pipelin off-set
pressur older drug roch receiv food drug
administr approv novel effect antibodi
therapi ocrevu relaps ms
compet primari progress ms
approv treatment littl off-label use
current drug add competit
landscap also benefit due roughli
royalti sale two third global
billion ms market exposur new ppm
indic biogen anti-lingo drug candid key part
ms pipelin drug could help repair myelin
sheath coat neuron give novel mechan
action potenti allow patient regain lost
function drug fail hit key endpoint
phase studi saw encourag data
clinic respons opicinumab continu move forward
develop oncolog expect partner
subcutan rituxan also next-gener drug
gazyva launch leukemia product
superior efficaci profil rituxan recent
approv larg indol first-lin lymphoma set
extend oncolog profit stream
individu odd approv mix bullish
novel broader neurolog rare-diseas
pipelin includ sever product high risk
spinraza launch annual price
lack treatment option rare deadli diseas
could creat billion market although
assum sale could peak around billion
spinraza begin share market novarti gene
therapi zolgensma divers pipelin follow
spinraza area includ ms next-gener fumar
vumer novel re-myelin therapi opicinumab
al follow mix
data aducanumab program alzheim
model probabl approv explicitli
model firm amyloid antibodi
think tau antibodi could see sale
billion approv treatment supranuclear palsi
assum probabl drug well
two tau-target therapi neurimmun
ioni develop alzheim give
exposur potenti new target diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
lead billion global ms market
avonex plegridi tysabri tecfidera
upcom launch vumer could help protect
tecfidera franchis gener competit
receiv royalti profit share roch
ms drug ocrevu cancer therapi rituxan
neurolog portfolio outsid ms includ
spinraza therapi sever neurolog
diseas includ parkinson al alzheim
help diversifi revenu boost sale growth
oinject ms therapi like avonex lost
edg brand oral competit gener
inject launch tysabri risk profil
make vulner patient switch roch
aducanumab halt march although
firm plan file approv launch far
certain demonstr high-risk natur
drive growth oral
competit roche/ptc gene therapi novarti
could threaten franchis beyond
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
year-end cash balanc billion free
cash flow billion annual help fund
futur repurchas allow firm flexibl size
futur acquisit firm cash invest
balanc sheet match similar amount debt
matur issu billion
debt help fund share-repurchas program
histor focus return excess cash
sharehold via buyback limit acquisit
collabor record strong expect tuck-in
acquisit go forward billion free cash
flow gener spent vast
major cash repurchas averag
repurchas price per share
profit depend four key blockbust
high-risk potenti high-reward pipelin
physician payer fail support gazyva use
rituxan despit strong superior data leukemia
larg lymphoma set roch could
vulner competit cheaper biosimilar rituxan
fourth-quart revenu
roch collabor feed directli bottom line
boost margin plegridi like help
maintain lead interferon market expect
gener copaxon weigh sale inject ms
therapi ms portfolio enjoy tremend
price power unit state insur could begin
find way put pressur futur price increas
competitor reach market avonex plegridi
exclud nation formulari
tecfidera sale see slower growth partli due
concern case pml gastrointestin issu
oral drug celgen ozanimod pois
enter market gener version tecfidera could enter
 market success ipr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
challeng decis expect mix result
alzheim therapi aducanumab phase trial also
demonstr high-risk natur
chosen area focu within neurolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
new york mellon corp
capit research manag compani
share
fund
share
fund
scango took ceo juli longtim
execut jame mullen serv ceo
development-stag biotech year
previous spend year bayer scango help
refocu pipelin neurodegen diseas
neurology-rel indic build strong team
neurolog drug discoveri emphas small tuck-in
commerci offic toni kingsley chief doug
left scango depart
begin decis spin firm
hemophilia franchis led specul firm
sale despit turnov chief medic offic alfr
sandrock decad experi support
pipelin recent ad titl execut vice
presid departur michael ehler
chief commerci offic career
longtim director william young step
role independ chairman replac stelio
papadopoulo chairman regulu
annual meet may overal see
board well qualifi divers independ despit
long tenur sever director applaud
effort emphas restrict stock option
compens packag top execut
believ align interest sharehold howev
take-over defens author prefer stock may
work interest sharehold complex right
agreement partner roch
trigger acquir could damp
enthusiasm potenti acquir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
take backseat aducanumab reviv
rais fve includ chanc approv oct
shock turn event third-quart
file food drug administr earli
base complet analysi two phase
studi engag emerg remov drug
valuat model march lower fair
valu estim per share firm
discontinu studi base futil analysi
howev new data discuss today earn
call persuad us add drug back model
instead prior probabl approv
uncertainti
surround weaker data engag studi result
rais fair valu estim per
share share remain under-valued despit
signific share appreci tuesday addit data
releas clinic trial alzheim diseas
meet decemb abl address concern
could return prior probabl approv
continu award wide moat base
stabil ms franchis diversif neurolog
spinraza solid neurolog pipelin although
highlight high uncertainti come
innov high-risk pipelin financi result quarter
support thesi growth ms revenu
spinraza growth driven ex-u uptak continu
assum tecfidera could see gener competit
base case hear novemb like
follow rule earli remain bullish
pipelin beyond aducanumab data readout begin
come frequent includ phase
parkinson data data recent acquir
dive deeper aducanumab stori develop
stop march futil analysi pool data
trial indic less
probabl meet primari endpoint howev
time alreadi indic emerg
studi trend posit engag
fulli realiz extent impact
protocol amend result trial analysi
releas today show data patient
aducanumab abl meet primari secondari
patient emerg studi engag studywhich
enrol earlier emerg impact
treatment protocol use prior amend
push patient toward lower dosesdid meet
endpoint analysi engag studi subset
patient receiv high uninterrupt dose drug
patient sometim suspend treatment due side
effect seem impli similar efficaci emerg
although caution statist around
analysi
data appear encourag assign
probabl approv given mani outstand question
make sens futil analysiswhich
smaller dataset skew toward first complet
mani receiv lower dose drug prior protocol
amendmentsdid tell full stori addit fda
board decis file approv
howev approv far certain still miss
key data could help explain continu
mysteri engag fail meet primari endpoint
high-dos patient emerg saw reduct
declin cognit function measur cdr-
sb rel placebo highli statist
signific understand patient treat
protocol amend receiv uninterrupt high
dose aducanumab best although engag studi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
remaind expect immin data
head-to-head studi vumer versu tecfidera
could give better case initi new patient
vumer longer solid ip protect
tecfidera drug show improv gastrointestin
toler current assum howev tecfidera
sale tecfidera vumer billion
well consensu estim also expect first
key tau data supranuclear palsi mid-stag data
lupu drug later year model lupu
sale given prior failur mix data anoth
compound develop ucb model
rel conserv sale psp program rise
high million year model
turn headwind expect biosimilar rituxan begin
weigh profit share cancer drug
second half spinraza growth begin
dip zolgensma get better reimburs access
 model gradual eros spinraza begin
zolgensma access improv label
expand includ older patient zolgensma current
approv patient age expect
pipelin progress acceler data
begin roll parkinson drug candid
nightstar gene therapi program nsr-
rpgr follow data al drug tofersen
start one month ahead emerg mean patient
advanc treatment protocol amend
encourag higher dose put place clear
differ enough explain data
month trial addit inform releas ctad
decemb shed light much
impact engag earlier enrol whether
signific differ number patient
receiv interrupt dose due known brain-
swell side effect amyloid plaqu reduct
two studi
strong highlight ms stabil pipelin
report strong result second quarter
rais guidanc full year slightli
increas fair valu estim per share
account recent share repurchas price
significantli fair valu estim lower tax rate
guidanc stronger perform model
ms franchis driven tecfidera
royalti revenu roch ocrevu advanc
pipelin sever potenti driver exclud
model includ lupu pain alzheim program
think share look under-valued recent price
howev caution signific near-term
uncertainti surround spinraza potenti declin
face new competit novarti sma gene therapi
zolgensma approv end may well
tecfidera patent litig like decis
valid key patent earli overal ms
franchis solid strategi expand adjac area
like neuromuscular movement disord well
immunolog ophthalmolog contribut wide
despit expect overhang tecfidera spinraza
uncertainti see potenti posit catalyst
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
